Paul Stoffels of Johnson & Johnson talks about the company’s broad HIV portfolio and the role of industry in advancing vaccine research.

Although challenges remain, the growing field of mRNA-based vaccine development seems to have a bright future, with potential for preventing cancer, flu, and HIV.

More HIV-infected people than ever before are receiving life-saving treatment. Despite this progress, HIV incidence rates remain virtually static.

We must continue to engage local investigators and develop their capacity to conduct more basic and clinical research on the African continent.

The battle against HIV/AIDS lost another great soldier recently with the passing of Australian immunologist and clinician David Cooper on March 18. Cooper was a pioneering scientist and champion for HIV treatment and prevention, and he left an indelible mark on the field he dedicated his career to. “He had a great skill in knowing…

Remembering Bonnie Mathieson: A champion of young scientists

In a few weeks, the AIDS 2018 meeting will kick off in Amsterdam. It will be the 22nd annual conference, and remains the largest international gathering focused on a single public health issue. This year, one message that will come out loud and clear is that more than 30 years later, AIDS isn’t over. As…

Marianne Mureithi is part of a team of researchers that just received highly competitive funding to study mucosal immune responses to HIV in Kenya.

Drone delivery may help overcome the challenge of getting medicines and vaccines to hard-to-reach populations.

Maria Grazia Pau, senior director, compound development team leader for HIV vaccine programs at the Janssen Pharmaceutical Companies of Johnson & Johnson, talks with IAVI Report about the start of the company’s Phase III Mosaico trial.